Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02864368|
Recruitment Status : Active, not recruiting
First Posted : August 12, 2016
Last Update Posted : November 27, 2020
Gary Archer Ph.D.
Annias Immunotherapeutics, Inc.
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Gary Archer Ph.D., Duke University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Active, not recruiting|
|Estimated Primary Completion Date :||February 2021|
|Estimated Study Completion Date :||September 2021|